Tumor News and Research

RSS

CWRU researchers find mechanism that enables LRAT enzyme to store vitamin A

Researchers at Case Western Reserve University School of Medicine have uncovered the mechanism that enables the enzyme Lecithin: retinol acyltransferase (LRAT) to store vitamin A — a process that is indispensable for vision.

12 Dec 2014

Study reveals how the human brain heals itself after surgical removal of brain tumor

An interdisciplinary team of neuroscientists and neurosurgeons from the University of Rochester has used a new imaging technique to show how the human brain heals itself in just a few weeks following surgical removal of a brain tumor.

11 Dec 2014

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

11 Dec 2014

Male hormone testosterone may increase risk of colon cancer

Previous cancer research has revealed that women are less likely than men to suffer from non-sex specific cancers such as cancer of the colon, pancreas and stomach. Scientists theorized that perhaps this trend was due to a protecting effect created by female hormones, such as estrogen, that help prevent tumors from forming. Now, researchers at the University of Missouri have found evidence suggesting that the male hormone testosterone may actually be a contributing factor in the formation of colon cancer tumors.

11 Dec 2014

Enzymatic activity essential for vision may provide target for drug transport

10 Dec 2014

Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.

10 Dec 2014

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ≥50 miles away from a cancer center, according to a study published in the December 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

In a groundbreaking new study, UCLA researchers have for the first time advanced a surgical technique performed with the help of a robot to successfully access a previously-unreachable area of the head and neck.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

$Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors$

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors.

9 Dec 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.

9 Dec 2014

Study finds that disarray in methylation helps tumors adapt to changing circumstances

The genetic tumult within cancerous tumors is more than matched by the disorder in one of the mechanisms for switching cells' genes on and off, scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.

9 Dec 2014

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

9 Dec 2014

BAZ2A protein directly influences the aggressiveness of prostate cancer

A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.

9 Dec 2014

Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer.

9 Dec 2014

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR.

9 Dec 2014

MD Anderson study sheds light on miR569 gene

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

9 Dec 2014

Tumor News and Research

CWRU researchers find mechanism that enables LRAT enzyme to store vitamin A

Study reveals how the human brain heals itself after surgical removal of brain tumor

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Male hormone testosterone may increase risk of colon cancer

Enzymatic activity essential for vision may provide target for drug transport

Myriad Genetics highlights three new studies at SABCS 2014

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Study finds that disarray in methylation helps tumors adapt to changing circumstances

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

Agent THZ1 shrinks human-like small cell lung tumors in mice

BAZ2A protein directly influences the aggressiveness of prostate cancer

Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

MD Anderson study sheds light on miR569 gene

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News